OmniSite BioDiagnostics Inc. (OmniSite) proposes to aid in the field diagnosis of soft tissue injuries of DOD troops by development of DNA aptamer-based assays for protein markers and hydroxylated amino acids in diluted whole blood. DNA aptamers arenovel, inexpensive replacement reagents for… More

OmniSite BioDiagnostics, Inc. (OmniSite), with Dr. Richard Lagow of the University of Texas at Austin, plan to develop a polymer electrolyte membrane (PEM) fuel cell based on microelectromechanical systems (MEMS) technology. Micromachining of silicon willbe used to prepare microelectrode array… More

OmniSite BioDiagnostics (OmniSite) proposes to continue development of DNAaptamers to early ice crystal nuclei by Systematic Evolution of Ligands byEXponential enrichment (SELEX), which will be used to prevent damage tohuman red blood cells (RBCs) during lyophilization, thereby increasing the… More

OmniSite BioDiagnostics (OmniSite) proposes to continue development of DNAaptamers to early ice crystal nuclei by Systematic Evolution of Ligands byEXponential enrichment (SELEX), which will be used to prevent damage tohuman red blood cells (RBCs) during lyophilization, thereby increasing the… More

OmniSite BioDiagnostics (OmniSite) proposes to develop artificial receptors composed of DNA oligomers (called ¿Aptamers") for binding and detecting algal toxins. DNA aptamers can be mass produced with relative ease compared to antibody production and purification. The aptamers will be 5'-Cy 5… More

"OmniSite BioDiagnostics, Inc. (OmniSite) proposes to develop DNA Aptamers to Bacillus anthracis (nonpathogenic Sterne strain) spores and staphylococcal enterotoxin B (SEB) by the SELEX process. Aptamers are less expensive than antibodies to produce, do notrequire animal hosts for production, can be… More

"OmniSite BioDiagnostics proposes to demonstrate and develop artificial receptors composed of DNA called "aptamers" to replace anti-B and T lymphocyte and cytokine antibodies for rabbit and guinea pig immunologic analyses. DNA aptamers will be generated bythe Systematic Evolution of Ligands by… More

OmniSite BioDiagnostics, Inc. (OmniSite) proposes to develop artificial receptors composed of DNA oligomers (called "aptamers") for binding and removal of organophosphorous and chlorinated pesticides. Aptamers will be generated by the systematic evolution of ligands by exponential enrichment (SELEX)… More

Omnisite BioDiagnostics (OmniSite) proposes to develop a handheld fluorescence polarization (FP) reader for genetic microarrays to assess transcriptional changes in the genes of radiation-exposed astronauts. The reader will be capable of extracting messenger RNA (mRNA) from the blood or other… More

Microgravity biotechnology applications are very promising, yet common bioanalytical tools such as ELISA are nonexistent for spacecraft. These powerful assays require numerous preparative sample dilutions prior to application to 96 open wells of a microtiter plate. The open wells are treated with… More

OmniSite proposes to continue Phase I effort to develop aptamer-based assays to anthrax spores and SEB for detection instruments based on ECL, FP, and FRET formats. OmniSite will compare the different assay formats to determine which of thesedemonstrates the most sensitivity and specificity, as… More

OmniSite BioDiagnostics Inc. (OmniSite) proposes to develop a novel DNA aptamer against glucose for the purpose of monitoring glucose levels in the rotating space bioreactor and eventually in astronauts or other human subjects. Aptamers are short (40?60 base) DNA or RNA chains selected from a… More

Countries hostile to the U.S. have or are in the process of developing or obtaining Weapons of Mass Destruction, in particular chemical and/or biological (CB) warfare agents, ¿asymmetric threats¿

OmniSite BioDiagnostics Inc. proposes to determine the feasibility of using DNA Aptamers to bind key germinant receptors on nonpathogenic Sterne strain anthrax spores to induce synchronous germination, hence leading to more effective antibiotic treatmentof inhalation anthrax. DNA Aptamers are short… More

OmniSite Biodiagnostics, Inc. and its parent company, Systems and Processes Engineering Corporation (SPEC), have extensive experience in both microfluidic, micromechanical (MEMS) and Fluorescence detection technologies. OmniSite proposes to design and prototype a compact, handheld and low power… More